XTalks

APRIL 29, 2022

At higher doses, Novo found that semaglutide could help patients lose weight by as much as seven percent, prompting the company to develop Saxenda (liraglutide). Saxenda has been the most successful obesity drug in the past decade, earning Novo $918 million in 2020. Wegovy had a price tag of $1,297 a month when it was first launched.

Trials 98

Trials Drugs FDA Approval Clinical Trials 98

Pharmaceutical Technology

NOVEMBER 30, 2022

The company’s weight loss drug Saxenda (liraglutide) won an approval for chronic weight management in December 2014, and Wegovy (semaglude) got the same tag in 2021. weight loss in obese or overweight individuals. Novo Nordisk is another company leading the charge in this field.

Drugs 264

Drugs Manufacturing Hormones Contract Manufacturing 264

Pharmaceutical Technology

NOVEMBER 30, 2022

The company’s weight loss drug Saxenda (liraglutide) won an approval for chronic weight management in December 2014, and Wegovy (semaglude) got the same tag in 2021. weight loss in obese or overweight individuals. Novo Nordisk is another company leading the charge in this field.

Drugs 246

Drugs Manufacturing Hormones Contract Manufacturing 246